FABP Inhibitor Program for Chemotherapy-Induced Peripheral Neuropathy & Various Cancers

Scientific and Clinical Validation

  • Fatty Acid Binding Protein (FABP) Inhibitor platform with high potency and selectivity (learn more about FABPs)
  • FABPs are intracellular proteins that chaperone lipids including endocannabinoids and fatty acids
  • In vivo efficacy in models of pain, anxiety, and inflammation through mechanisms involving the endocannabinoid system
  • In vivo efficacy in animal models of prostate cancer through mechanisms involving the regulation of pro-tumoral and pro-metastatic proteins
  • FABP5 inhibition may have therapeutic value in Chemotherapy-Induced Peripheral Neuropathy
  • FABP5 is a validated target in breast, prostate and cervical cancers, and is implicated in many other cancer types

Learn more about ART26.12

Formulation and Intellectual Property

  • Three patents issued
  • 14 patent applications pending, with two additional planned


  • Chemotherapy-Induced Peripheral Neuropathy
  • Prostate cancer
  • Breast cancer
  • Other cancers
  • Pain/Inflammation
  • Anxiety/PTSD


  1. Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia. Zilbermint MF, Dobs AS, Future Oncol. 2009 Oct; 5(8):1211-20;
  2. Data from Market Intel Reports 2016 as quoted in Innovus Pharma to Enter the Oncology Supportive Care Market With an Exclusive License to Two GRAS-Listed OTC Compounds for Cachexia and Muscle Growth and Repair From the University of Iowa Research Foundation. Innovus Press Release June 6, 2017, ex-US estimate based upon market forecast model from US sales figures;
  3. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials. Advani, Shailesh M et al., BMC cancer vol. 18,1 1174. 27 Nov. 2018, doi:10.1186/s12885-018-5080-4;
  4. Sánchez‐Lara K, Ugalde‐Morales E, Motola‐Kuba D, Green D. Gastrointestinal symptoms and weight loss in cancer patients receiving chemotherapy. Br J Nutr 2013;109:894‐7,
  5. Management of Cancer Cachexia: ASCO Guideline, May 2020;
  6. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD004310.
  9. Source: AstraZeneca, adMare. Data on file